Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04701918 · ClinicalTrials.gov registry record · Phase 2
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT04701918: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04701918 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04701918, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
Primary Outcome
Evaluate objective response rate of non-ablated lesion(s) for combination pembrolizumab/avelumab and adjunctive cryoablation per RECIST v1.1 criteria
Interventions
- DRUG Pembrolizumab
- PROCEDURE Cryoablation
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 2 |
What the finished NCT04701918 record still lists
NCT04701918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04701918 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04701918 about?
NCT04701918 is a clinical study titled "Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma". This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
What is the current status of trial NCT04701918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2021-06-04. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT04701918?
The interventions under investigation include: Pembrolizumab (DRUG), Cryoablation (PROCEDURE), Avelumab (DRUG).
Who is sponsoring clinical trial NCT04701918?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04701918's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI